Key result
Generic and original clopidogrel show no difference in platelet aggregation or major cardiac events post-DES.
Why the study?
The study was conducted to compare the antiplatelet efficacy of original clopidogrel and its generic analogue after the implantation of Russian drug-eluting stents.
Does generic clopidogrel provide similar antiplatelet efficacy compared to original clopidogrel in patients after implantation of Russian drug-eluting stents?
Cohort
Does generic clopidogrel provide similar antiplatelet efficacy compared to original clopidogrel in patients after implantation of Russian drug-eluting stents?
Answers are grounded in this paper and cite their sources.
Generic clopidogrel demonstrates comparable antiplatelet efficacy and clinical safety to original clopidogrel following implantation of Russian drug-eluting stents.
OBJECTIVE To compare antiplatelet efficacy of original clopidogrel and its generic analogue after implantation of Russian drug-eluting stents. MATERIAL AND METHODS Considering ADP-induced platelet aggregation, we compared aggregation in 3 and 30 days after intake of original and generic clopidogrel. RESULTS After 3 days, ADP-induced platelet aggregation was 36.5% and 39.1%, after a month — 38.9% and 43.7%, respectively. There were no major cardiac events (cardiac death, non-fatal acute myocardial infarction, stroke, stent thrombosis, stent restenosis, repeated target vessel revascularization, recurrence or progression of angina pectoris) throughout 12-52 months after stenting. CONCLUSION We found no significant between-group difference in ADP-induced platelet aggregation and incidence of major cardiac events.
No takes yet. Share an insight, caveat, or question.
Rustomyan et al. (2024) conducted a cohort in Patients after implantation of drug-eluting coronary stents. Original clopidogrel vs. Generic clopidogrel was evaluated on ADP-induced platelet aggregation at 30 days. Original and generic clopidogrel showed no significant difference in ADP-induced platelet aggregation at 30 days or incidence of major cardiac events after drug-eluting stenting.
Synapse has enriched 10 related papers. Consider them for comparative context: